- Home
- KALV vs GLUE Comparison
KALV vs GLUE Comparison
Compare KALV & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- GLUE
- Stock Information
- Founded
- KALV N/A
- GLUE 2019
- Country
- KALV United States
- GLUE United States
- Employees
- KALV N/A
- GLUE N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- GLUE Health Care
- Exchange
- KALV Nasdaq
- GLUE Nasdaq
- Market Cap
- KALV 362.2M
- GLUE 407.3M
- IPO Year
- KALV N/A
- GLUE 2021
- Fundamental
- Price
- KALV $10.03
- GLUE $6.22
- Analyst Decision
- KALV Strong Buy
- GLUE Buy
- Analyst Count
- KALV 8
- GLUE 3
- Target Price
- KALV $25.67
- GLUE $12.67
- AVG Volume (30 Days)
- KALV 321.8K
- GLUE 512.9K
- Earning Date
- KALV 03-10-2025
- GLUE 03-13-2025
- Dividend Yield
- KALV N/A
- GLUE N/A
- EPS Growth
- KALV N/A
- GLUE N/A
- EPS
- KALV N/A
- GLUE N/A
- Revenue
- KALV N/A
- GLUE $14,975,000.00
- Revenue This Year
- KALV N/A
- GLUE N/A
- Revenue Next Year
- KALV N/A
- GLUE N/A
- P/E Ratio
- KALV N/A
- GLUE N/A
- Revenue Growth
- KALV N/A
- GLUE N/A
- 52 Week Low
- KALV $7.30
- GLUE $3.21
- 52 Week High
- KALV $15.50
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- KALV 59.09
- GLUE 44.90
- Support Level
- KALV $8.99
- GLUE $6.42
- Resistance Level
- KALV $11.00
- GLUE $7.22
- Average True Range (ATR)
- KALV 0.57
- GLUE 0.43
- MACD
- KALV 0.11
- GLUE 0.03
- Stochastic Oscillator
- KALV 57.08
- GLUE 19.35
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.